Large-Scale Funding Rises In Korea Amid Biotech Investment Boom
Interest Persists After Record VC Investment In 2020
After record venture capital activity around South Korean biotechs last year, the strong investment interest has persisted so far this year, with an increased number of companies receiving large-scale funding as the promising sector emerges amid the pandemic.
You may also be interested in...
Vaccine specialist SK Bioscience is set to launch potentially South Korea’s biggest biopharma IPO next month on the back of a growing premium vaccine business, new opportunities in COVID-19 vaccines and its contract manufacturing operations.
PharmaVentures’ Adrian Dawkes talks about how COVID-19 will impact pharma deals going forward and how Korean firms in particular may be able to grab opportunities in the global arena.
The Bio Korea meeting included a discussion around the challenges faced by Korean developers of COVID-19 therapies and vaccines and how they should approach the global market. Cooperation and production technology will be key.